Logo image of AVRO

AVROBIO INC (AVRO) Stock Fundamental Analysis

NASDAQ:AVRO - Nasdaq - US05455M1009 - Common Stock - Currency: USD

1.4  -0.02 (-1.41%)

After market: 1.45 +0.05 (+3.57%)

Fundamental Rating

3

Taking everything into account, AVRO scores 3 out of 10 in our fundamental rating. AVRO was compared to 566 industry peers in the Biotechnology industry. AVRO has a great financial health rating, but its profitability evaluates not so good. AVRO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AVRO has reported negative net income.
In the past year AVRO has reported a negative cash flow from operations.
In the past 5 years AVRO reported 4 times negative net income.
AVRO had a negative operating cash flow in each of the past 5 years.
AVRO Yearly Net Income VS EBIT VS OCF VS FCFAVRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

AVRO has a better Return On Assets (32.82%) than 99.65% of its industry peers.
Looking at the Return On Equity, with a value of 34.11%, AVRO belongs to the top of the industry, outperforming 98.60% of the companies in the same industry.
Industry RankSector Rank
ROA 32.82%
ROE 34.11%
ROIC N/A
ROA(3y)-49.45%
ROA(5y)-45.78%
ROE(3y)-65.96%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
AVRO Yearly ROA, ROE, ROICAVRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400 -500

1.3 Margins

AVRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVRO Yearly Profit, Operating, Gross MarginsAVRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

AVRO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AVRO has been increased compared to 5 years ago.
There is no outstanding debt for AVRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVRO Yearly Shares OutstandingAVRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AVRO Yearly Total Debt VS Total AssetsAVRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

AVRO has an Altman-Z score of 2.61. This is not the best score and indicates that AVRO is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of AVRO (2.61) is better than 74.48% of its industry peers.
AVRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.61
ROIC/WACCN/A
WACCN/A
AVRO Yearly LT Debt VS Equity VS FCFAVRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

AVRO has a Current Ratio of 26.17. This indicates that AVRO is financially healthy and has no problem in meeting its short term obligations.
AVRO has a better Current ratio (26.17) than 95.98% of its industry peers.
A Quick Ratio of 26.17 indicates that AVRO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 26.17, AVRO belongs to the top of the industry, outperforming 95.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 26.17
Quick Ratio 26.17
AVRO Yearly Current Assets VS Current LiabilitesAVRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.57% over the past year.
EPS 1Y (TTM)49.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVRO will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.25% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.01%
EPS Next 2Y37.49%
EPS Next 3Y25.45%
EPS Next 5Y16.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVRO Yearly EPS VS EstimatesAVRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AVRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVRO Price Earnings VS Forward Price EarningsAVRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVRO Per share dataAVRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as AVRO's earnings are expected to grow with 25.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.49%
EPS Next 3Y25.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVROBIO INC

NASDAQ:AVRO (6/20/2024, 8:00:00 PM)

After market: 1.45 +0.05 (+3.57%)

1.4

-0.02 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2024-05-09/amc
Earnings (Next)08-08 2024-08-08/amc
Inst Owners1.37%
Inst Owner Change0%
Ins Owners10.53%
Ins Owner Change0%
Market Cap62.85M
Analysts80
Price Target2.04 (45.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.45%
Min EPS beat(2)41.76%
Max EPS beat(2)59.15%
EPS beat(4)2
Avg EPS beat(4)-84.15%
Min EPS beat(4)-385.28%
Max EPS beat(4)59.15%
EPS beat(8)3
Avg EPS beat(8)-44.36%
EPS beat(12)5
Avg EPS beat(12)-29.9%
EPS beat(16)7
Avg EPS beat(16)-21.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)26.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 32.82%
ROE 34.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.45%
ROA(5y)-45.78%
ROE(3y)-65.96%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.17
Quick Ratio 26.17
Altman-Z 2.61
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)65.25%
Cap/Depr(5y)96.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.68%
EPS Next Y69.01%
EPS Next 2Y37.49%
EPS Next 3Y25.45%
EPS Next 5Y16.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.86%
OCF growth 3YN/A
OCF growth 5YN/A